News
5 September, 2024
Dementia Australia welcomes UK approval of Alzheimer drug
Dementia Australia has welcomed the approval of Lecanemab by the UK’s Medicines and Healthcare Products Regulatory Agency.
Lecanemab, a drug that slows the progression of early Alzheimer’s disease by removing amyloid plaques from the brain, is currently under evaluation by Australia’s Therapeutic Goods Administration.
Professor Christopher Rowe, director of the Australian Dementia Network (ADNeT), called the approval “an exciting and historic first step” towards reducing Alzheimer’s impact.
“ADNeT looks forward to this and other promising treatments under development that together may make a substantial positive change,” he said.
Dementia Australia CEO Professor Tanya Buchanan expressed hope for its approval in Australia, noting that while Lecanemab may not be suitable for everyone, it offers new hope for those affected by dementia.
“This is an exciting time in the field,” Buchanan said.
“While Lecanemab will not be a magic bullet, it represents the first step towards effective treatments.”
